Deliver Your News to the World

Mammoth Biosciences Co-Founder Professor Jennifer Doudna Wins Nobel Prize in Chemistry for CRISPR Discovery

As Co-founder and Chair of the Scientific Advisory Board at Mammoth, Professor Doudna continues to drive new Cas protein discoveries and applications across diagnostics and therapeutics

South San Francisco, Calif. – WEBWIRE

Mammoth Biosciences, Inc.’s Co-founder and Chair of the Scientific Advisory Board, Professor Jennifer Douda today won the Nobel Prize in Chemistry with colleague Professor Emmanuel Charpentier for their discovery of the genome editing tool CRISPR-Cas9. At Mammoth, Prof. Doudna continues to pioneer new Cas protein discoveries and applications across diagnostics and therapeutics and guide the company’s scientific vision. 

“On behalf of the whole team at Mammoth, we congratulate Jennifer on the massive achievement and are honored to work with such a brilliant scientist and industry pioneer,” remarks fellow Co-founder and CTO of Mammoth, Janice Chen. “My Co-founder Lucas Harrington and I are grateful for our Ph.D. training in Jennifer’s lab at UC Berkeley. Now, as we lead the company alongside her, I can personally attest that she’s been a significant role model and mentor to myself and other women in STEM. This recognition is incredibly well deserved and highlights the trailblazer that Jennifer is.” 

Prof. Doudna co-founded Mammoth in 2018 with the vision of advancing these discoveries into revolutionary tools that will reshape research and healthcare. She also continues to advance the CRISPR field, having driven the discovery and development of novel Cas enzymes like Cas12, Cas13, Cas14 and Casɸ. With exclusive licenses to these enzymes from the University of California, Berkeley, Mammoth is building the next generation of CRISPR tools, with expanding applications across diagnostics, gene-editing, and therapeutics. 

In addition to Prof. Doudna’s recent honor, Mammoth’s other Co-founders Dr. Trevor Martin, Dr. Janice Chen, and Dr. Lucas Harrington, have also been recognized for transforming the future of healthcare in Business Insider’s 30 Under 40. The company’s first CRISPR-based product, DETECTRTM -- which can search and identify disease in rapid, accurate, and accessible formats -- has also been awarded Best COVID Diagnostics Testing Solution by the University of California, San Francisco. 

To help advance Jennifer Doudna’s vision at Mammoth and learn about the company’s latest innovations, visit

About Mammoth Biosciences

Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. By leveraging its internal research and development and exclusive licensing to patents related to Cas12, Cas13, Cas14 and Casɸ, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Decheng, Mayfield, NFX, and 8VC, and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

( Press Release Image: )


 Mammoth Biosciences
 Jennifer Doudna

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.